Graff P, Crehange G
Département d'oncologie radiothérapie, Institut Curie, 26, rue d'Ulm, 75005 Paris, France.
Département d'oncologie radiothérapie, Institut Curie, 26, rue d'Ulm, 75005 Paris, France.
Cancer Radiother. 2021 Oct;25(6-7):684-691. doi: 10.1016/j.canrad.2021.06.028. Epub 2021 Jul 14.
Still an emerging approach a few years ago, stereotactic body radiation therapy (SBRT) has ranked as a valid option for the treatment of localized prostate cancer. Inherent properties of prostatic adenocarcinoma (low α/β) make it the perfect candidate. We propose a critical review of the literature trying to put results into perspective to identify their strengths, limits and axes of development. Technically sophisticated, the stereotactic irradiation of the prostate is well tolerated. Despite the fact that median follow-up of published data is still limited, ultra-hypofractionated radiotherapy seems very efficient for the treatment of low and intermediate risk prostate cancers. Data seem satisfying for high-risk cancers as well. New developments are being studied with a main interest in treatment intensification for unfavorable intermediate risk and high-risk cancers. Advantage is taken of the sharp dose gradient of stereotactic radiotherapy to offer safe reirradiation to patients with local recurrence in a previously irradiated area.
立体定向体部放射治疗（SBRT）几年前还是一种新兴的治疗方法，如今已成为治疗局限性前列腺癌的有效选择。前列腺腺癌的固有特性（低α/β）使其成为理想的治疗对象。我们对相关文献进行了批判性综述，试图全面看待研究结果，以确定其优势、局限性和发展方向。前列腺的立体定向放射治疗技术复杂，但耐受性良好。尽管已发表数据的中位随访时间仍然有限，但超分割放疗似乎对低危和中危前列腺癌的治疗非常有效。高危癌症的数据似乎也令人满意。目前正在研究新的进展，主要关注对不良中危和高危癌症的强化治疗。利用立体定向放射治疗的陡峭剂量梯度，为先前接受过照射区域出现局部复发的患者提供安全的再照射。
